Exact Mass: 532.2437216
Exact Mass Matches: 532.2437216
Found 147 metabolites which its exact mass value is equals to given mass value 532.2437216
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)
PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)
PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)
PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
bistratamide F
A homodetic cyclic peptide that consists of L-threonine and L-valine and L-serine as the amino acid residues cyclised via amide bonds. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line
(9R)-2beta,9-dihydroxymegastigma-4,7-dien-3-one 9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
(6S,7R,Ra)-3-phenylacrylic acid 2,3,10,11,12-pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-1-yl ester|neglschisandrin A
(6R,9R)-3-oxo-alpha-ionol-9-O-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranoside
Ala Ala Trp Trp
Ala Trp Ala Trp
Ala Trp Trp Ala
Cys Lys Pro Trp
Cys Lys Trp Pro
Cys Pro Lys Trp
Cys Pro Trp Lys
Cys Trp Lys Pro
Cys Trp Pro Lys
Asp Gly Arg Trp
C23H32N8O7 (532.2393841999999)
Asp Gly Trp Arg
C23H32N8O7 (532.2393841999999)
Asp Arg Gly Trp
C23H32N8O7 (532.2393841999999)
Asp Arg Trp Gly
C23H32N8O7 (532.2393841999999)
Asp Trp Gly Arg
C23H32N8O7 (532.2393841999999)
Asp Trp Arg Gly
C23H32N8O7 (532.2393841999999)
Glu Glu Lys Gln
Glu Glu Gln Lys
Glu Lys Glu Gln
Glu Lys Gln Glu
Glu Gln Glu Lys
Glu Gln Lys Glu
Phe His Met Val
Phe His Val Met
Phe Met His Val
Phe Met Val His
Phe Val His Met
Phe Val Met His
Gly Asp Arg Trp
C23H32N8O7 (532.2393841999999)
Gly Asp Trp Arg
C23H32N8O7 (532.2393841999999)
Gly Arg Asp Trp
C23H32N8O7 (532.2393841999999)
Gly Arg Trp Asp
C23H32N8O7 (532.2393841999999)
Gly Trp Asp Arg
C23H32N8O7 (532.2393841999999)
Gly Trp Arg Asp
C23H32N8O7 (532.2393841999999)
His Phe Met Val
His Phe Val Met
His Met Phe Val
His Met Val Phe
His Val Phe Met
His Val Met Phe
Lys Cys Pro Trp
Lys Cys Trp Pro
Lys Glu Glu Gln
Lys Glu Gln Glu
Lys Pro Cys Trp
Lys Pro Trp Cys
Lys Gln Glu Glu
Lys Trp Cys Pro
Lys Trp Pro Cys
Met Phe His Val
Met Phe Val His
Met His Phe Val
Met His Val Phe
Met Val Phe His
Met Val His Phe
Pro Cys Lys Trp
Pro Cys Trp Lys
Pro Lys Cys Trp
Pro Lys Trp Cys
Pro Trp Cys Lys
Pro Trp Lys Cys
Gln Glu Glu Lys
Gln Glu Lys Glu
Gln Lys Glu Glu
Arg Asp Gly Trp
C23H32N8O7 (532.2393841999999)
Arg Asp Trp Gly
C23H32N8O7 (532.2393841999999)
Arg Gly Asp Trp
C23H32N8O7 (532.2393841999999)
Arg Gly Trp Asp
C23H32N8O7 (532.2393841999999)
Arg Trp Asp Gly
C23H32N8O7 (532.2393841999999)
Arg Trp Gly Asp
C23H32N8O7 (532.2393841999999)
Val Phe His Met
Val Phe Met His
Val His Phe Met
Val His Met Phe
Val Met Phe His
Val Met His Phe
Trp Ala Ala Trp
Trp Ala Trp Ala
Trp Cys Lys Pro
Trp Cys Pro Lys
Trp Asp Gly Arg
C23H32N8O7 (532.2393841999999)
Trp Asp Arg Gly
C23H32N8O7 (532.2393841999999)
Trp Gly Asp Arg
C23H32N8O7 (532.2393841999999)
Trp Gly Arg Asp
C23H32N8O7 (532.2393841999999)
Trp Lys Cys Pro
Trp Lys Pro Cys
Trp Pro Cys Lys
Trp Pro Lys Cys
Trp Arg Asp Gly
C23H32N8O7 (532.2393841999999)
Trp Arg Gly Asp
C23H32N8O7 (532.2393841999999)
Trp Trp Ala Ala
Ametantrone acetate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents
2-((2-((1-(2-(Dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide
(2R,6S)-2-amino-6-[[(4R)-4-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-7-[[(2R)-1-[[(1R)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid
methyl (2S,3R,4S)-3-ethyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate
2-[(3S,6aS,8R,10aS)-1-[(2-fluorophenyl)-oxomethyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-phenylphenyl)methyl]acetamide
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
11-isopropyl-4,7,14-trimethyl-18-(sec-butyl)-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
(4s)-4-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}but-1-en-1-yl]-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one
3-(3,4-dihydroxyphenyl)-n-[4,7,10-trihydroxy-2,9,13-trimethyl-6-(2-methylpropyl)-14-oxo-1-oxa-5,8,11-triazacyclotetradeca-4,7,10-trien-3-yl]prop-2-enimidic acid
(9s,10r)-4,5,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl (2e)-3-phenylprop-2-enoate
(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one
{"Ingredient_id": "HBIN010856","Ingredient_name": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one","Alias": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-1-cyclohex-2-enone; (4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-cyclohex-2-en-1-one","Ingredient_formula": "C25H40O12","Ingredient_Smile": "NA","Ingredient_weight": "532.58","OB_score": "30.24475007","CAS_id": "81425-28-7","SymMap_id": "SMIT13678","TCMID_id": "NA","TCMSP_id": "MOL012966","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(3s)-5-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r)-4-[(1s)-2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxy}oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
(1r,2s,3r,4s,6r,7r,8r,9r,12s,13s)-9,12-bis(acetyloxy)-3-(chloromethyl)-3,13-dihydroxy-6-isopropyl-9,13-dimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl acetate
C26H41ClO9 (532.2438966000001)
(4r)-3,5,5-trimethyl-4-[(1e,3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}but-1-en-1-yl]cyclohex-2-en-1-one
4-(3-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}but-1-en-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one
5-{[3,5-dihydroxy-2-(hydroxymethyl)-6-({4-[2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl}oxy)oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
(4s,7r,8s,11s,15s,18s)-4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol
(2e)-4-[(1r,5s,7r)-1-[(2s,3e,5r,6z)-7-chloro-5,9-dihydroxynona-3,6-dien-2-yl]-6-azaspiro[4.5]decan-7-yl]-2-methyl-n-(2-sulfoethyl)but-2-enimidic acid
C25H41ClN2O6S (532.2373716000001)